C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 251/70 (2006.01) A61K 31/427 (2006.01) A61K 31/429 (2006.01) A61K 31/53 (2006.01) A61P 3/04 (2006.01) A61P 7/04 (2006.01) A61P 9/12 (2006.01) C07D 277/28 (2006.01) C07D 401/12 (2006.01) C07D 403/12 (2006.01) C07D 409/12 (2006.01) C07D 413/12 (2006.01) C07D 417/04 (2006.01) C07D 417/12 (2006.01) C07D 417/14 (2006.01) C07D 513/04 (2006.01)
Patent
CA 2371274
This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.
L'invention concerne des dérivés de triazine, des composés bicycliques et tricycliques qui servent d'antagonistes sélectifs pour un récepteur de NPY (Y5). L'invention concerne également une composition pharmaceutique contenant une quantité thérapeutiquement efficace d'un composé de l'invention et un support pharmaceutiquement efficace. Cette composition est obtenue par combinaison d'une quantité thérapeutiquement efficace d'un composé de l'invention et d'un support pharmaceutiquement efficace. L'invention concerne en outre un procédé de préparation de cette composition pharmaceutique consistant à combiner une quantité thérapeutiquement efficace d'un composé de l'invention et un support pharmaceutiquement efficace. L'invention concerne finalement l'utilisation d'un composé de l'invention pour préparer une composition pharmaceutique dans le but de traiter toute anomalie susceptible d'être palliée par la réduction de l'activité d'un récepteur humain d'Y5.
Desai Mahesh N.
Marzabadi Mohammad R.
Noble Stewart A.
Wong Wai C.
H. Lundbeck A/s
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
Synaptic Pharmaceutical Corporation
LandOfFree
Selective npy (y5) antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective npy (y5) antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective npy (y5) antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1655164